Clinicopathological and prognostic significance of XPO1 in solid tumors: meta-analysis and TCGA analysis.

Exportin 1 (XPO1) is overexpressed in several solid tumors, and is associated with poor prognosis. Here, we aimed to evaluate the implication of XPO1 expression in solid tumors through a meta-analysis. PubMed, Web of Science, and Embase databases were searched for articles published until February 2023. Statistical data of the patients, odds ratios and hazard ratios (HRs), together with their corresponding 95% confidence intervals (CIs) were pooled to assess clinicopathological features and survival outcomes. Besides, the Cancer Genome Atlas (TCGA) was used to explore the prognostic significance of XPO1 in solid tumors. A total of 22 works, comprising 2595 patients were included in this study. The results suggested that increased XPO1 expression was associated with a higher tumor grade, more lymph node metastasis, advanced tumor stage, and progressively worse total clinical stage. Additionally, high XPO1 expression was associated with worse overall survival (OS) (HR = 1.43, 95% CI = 1.12-1.81, P = 0.004) and shorter progression-free survival (HR = 1.40, 95% CI = 1.07-1.84, P = 0.01). An analysis using the TCGA dataset showed that high XPO1 expression was associated with poor OS and disease-free survival. XPO1 is a promising prognostic biomarker and may constitute a therapeutic target for solid tumors.PROSPERO registration number: CRD42023399159.

Citation

Yang Tan, Gang Chen, Rong-Quan He, Zhi-Guang Huang, Yi-Wu Dang, Jia-Yuan Luo, Wan-Ying Huang, Su-Ning Huang, Run Liu, Zhen-Bo Feng. Clinicopathological and prognostic significance of XPO1 in solid tumors: meta-analysis and TCGA analysis. Expert review of molecular diagnostics. 2023 Jul-Dec;23(7):607-618

Mesh Tags

Substances

PMID: 37335774

search → result